[1].Min Gao, et al. Chemical geneics strategy identifies an HCV NS5A inhibitor with a potent clinical efect Nature. 2010 May 6,465(7294) 96-100.
[2]. David B Ascher, et al. Potent hepatistis C inhibitors bind directly to NS5A and reduce its affinity for RNA. Sci Rep. 2014 Apr 23,4.4765.
[3]. Tomomi Furihalta, et al. Different finteration profiles of direct acting anti-hepatitis C virus agents with human organic anion transporting polypeptides. Antimicrob Agents Chemother. 2014 Aug; 58(8):4555-64.
[4]. Kai Y, et al. Emergence of hepatitis C virus NS5A L31V plus Y93H variant upon treatment failure of daclatasvir and asunaprevir is relatively resistant to ledipasvir and NS5B polymerase nucleotide inhibitor GS-558093 in human hepatocyte chimeric mice. J Gastroenterol. 2015 Nov;50(11):1145-51.
[5] SeumgHon Le,et al. HA1077 displays synergistic activity with daclatasvir against hepatis C virus and suppresses the emergence of NS5A resistance-associated substitutions in mice. Sci Rep. 2018 Aug 20;8(1):12469.